12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ErepoXen: Phase II started

Xenetic began an open-label, New Zealand and Australian Phase II trial to evaluate multiple doses of ErepoXen in up to 72 adults with CKD who are...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >